Therapeutic developments in the treatment of amyotrophic lateral sclerosis. - Wikidata - wikimedia - TriplyDB

Therapeutic developments in the treatment of amyotrophic lateral sclerosis.

Therapeutic developments in the treatment of amyotrophic lateral sclerosis.

http://www.wikidata.org/entity/Q34974850

about

Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS Potential therapeutic drugs and methods for the treatment of amyotrophic lateral sclerosis.Riluzole-triggered GSH synthesis via activation of glutamate transporters to antagonize methylmercury-induced oxidative stress in rat cerebral cortex.Serotonergic mechanisms in amyotrophic lateral sclerosis.Neurotrophic natural products: chemistry and biology.Specific regulation of rat glial cell line-derived neurotrophic factor gene expression by riluzole in C6 glioma cells.Loss of metabotropic glutamate receptor-mediated regulation of glutamate transport in chemically activated astrocytes in a rat model of amyotrophic lateral sclerosis.

P2860

Q24297462-E40A265B-99D2-415A-8241-BB4271B9EC68 Q34276055-D2D16222-EAFF-4655-B166-F6652F93FEDC Q36204023-0369152D-ED44-49C8-8F38-3A8357D145D8 Q36544155-7A313BB3-C5F8-47D4-AA23-59FB3C97A16A Q37623342-358391B8-A8E5-40A8-BC8F-2BBAD0493DCD Q40307571-A5F1634C-131E-43C5-A148-65478B9277F7 Q46863053-AB2247BA-B4EA-4178-9100-961D3543E73A

P2860

Therapeutic developments in the treatment of amyotrophic lateral sclerosis.

http://www.wikidata.org/entity/Q34974850

description

2002 nî lūn-bûn

@nan

2002 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2002 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2002年の論文

@ja

2002年学术文章

@wuu

2002年学术文章

@zh-cn

2002年学术文章

@zh-hans

2002年学术文章

@zh-my

2002年学术文章

@zh-sg

2002年學術文章

@yue

name

Therapeutic developments in the treatment of amyotrophic lateral sclerosis.

@ast

Therapeutic developments in the treatment of amyotrophic lateral sclerosis.

@en

Therapeutic developments in the treatment of amyotrophic lateral sclerosis.

@nl

type

label

Therapeutic developments in the treatment of amyotrophic lateral sclerosis.

@ast

Therapeutic developments in the treatment of amyotrophic lateral sclerosis.

@en

Therapeutic developments in the treatment of amyotrophic lateral sclerosis.

@nl

prefLabel

Therapeutic developments in the treatment of amyotrophic lateral sclerosis.

@ast

Therapeutic developments in the treatment of amyotrophic lateral sclerosis.

@en

Therapeutic developments in the treatment of amyotrophic lateral sclerosis.

@nl

P1433

Q34974850-0DD04ED1-EED4-44EE-BA0A-229679AFBCB9

P1476

Q34974850-E047C616-3E82-410C-AD21-5C44F76F338B

P2093

Q34974850-0F0540CE-9023-464B-9FFF-0330FABCA2A7

Q34974850-3028B0D8-BFC0-4057-A460-E0AAA028051D

Q34974850-8BCF834A-4413-4FC2-B7B1-7DBEB7D97F7D

P2860

Q34974850-02F5B852-400B-4F04-8F4F-6ABD9659EEEF

Q34974850-03F93E1B-6248-43A9-AD47-26D02127EEE8

Q34974850-0C178218-F7AC-4700-86DA-A7F58F2059A9

Q34974850-0CFAB8A4-E843-42ED-8E98-64F41ED20A99

Q34974850-0D7291BD-8416-4F3A-9735-E5AB3271CDB4

Q34974850-0F21F7A1-6C38-4F82-AADE-0422C678B027

Q34974850-108E385B-AF5F-4423-9187-95FEFA2F7773

Q34974850-10C9ECFB-DD82-4D26-9512-732C86DC95F4

Q34974850-1271E6D8-E213-40B8-9E25-CBD31909F859

Q34974850-129F89A2-5401-458A-AA73-9C8764E82A3F

P304

Q34974850-032C41A0-DCD6-4E16-800F-9B1B93087EED

P31

Q34974850-1521B723-2AEE-48D5-B418-E6800ED8DBA5

P356

Q34974850-86F3F6D6-D3C6-457F-B2EB-1E2475DC6EAC

P407

Q34974850-2064C15F-AF10-4DA1-A689-EAB4A5C3B056

P433

Q34974850-995F8EDB-EBFD-4F56-AC87-076CB72FFF7C

P478

Q34974850-EC2330A6-735E-469D-AB58-11F3A5FC8865

P577

Q34974850-4606D8ED-B113-4C34-8504-67A62033E6AF

P698

Q34974850-52E95502-6407-403E-BF87-1D724F488751

P921

Q34974850-39C04216-4776-4394-8B16-FC3AA52ED106

P356

13543784.11.10.1343

P1433

Expert Opinion on Investigational Drugs

P1476

Therapeutic developments in the treatment of amyotrophic lateral sclerosis.

@en

P2093

Jeffrey D Rothstein

http://www.w3.org/2001/XMLSchema#string

Jerònia Lladó

http://www.w3.org/2001/XMLSchema#string

Mandy Jackson

http://www.w3.org/2001/XMLSchema#string

P2860

A gene encoding a putative GTPase regulator is mutated in familial amyotrophic lateral sclerosis 2

Developing motor neurons rescued from programmed and axotomy-induced cell death by GDNF

Infantile-onset ascending hereditary spastic paralysis is associated with mutations in the alsin gene

Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis

Glutamate transporter EAAT2 splice variants occur not only in ALS, but also in AD and controls

The gene encoding alsin, a protein with three guanine-nucleotide exchange factor domains, is mutated in a form of recessive amyotrophic lateral sclerosis

Modulation of the neuronal glutamate transporter EAAC1 by the interacting protein GTRAP3-18

Modulation of the neuronal glutamate transporter EAAT4 by two interacting proteins

GDNF: a potent survival factor for motoneurons present in peripheral nerve and muscle

Aberrant RNA processing in a neurodegenerative disease: the cause for absent EAAT2, a glutamate transporter, in amyotrophic lateral sclerosis

P304

1343-1364

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/13543784.11.10.1343

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

11

http://www.w3.org/2001/XMLSchema#string

P577

2002-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

12387699

http://www.w3.org/2001/XMLSchema#string

P921

amyotrophic lateral sclerosis